메뉴 건너뛰기

(주)서호 KS Q ISO/IEC 17025 국제공인교정기관 제약분야전문교정기관

식품관련자료

해외 각국 정부, 주요 언론이 발표한 식품안전 정책, 법령, 사건, 사고, 연구조사 결과 등 최신 정보를 제공합니다.

머리말 ················································································································1
II. 신약 및 자료제출의약품 ······································································2
1. 임상약리시험 (PHASE I) ·········································································2
가. 원료의약품 (DRUG SUBSTANCE)
1) 일반정보 (General Information) ······························································2
2) 제조원 (Manufacturer(s)) ··········································································3
3) 제조공정 및 공정관리 (Description of Manufacturing Process and
Process Controls) ·····························································································3
4) 불순물 (Impurities) ·····················································································3
5) 규격 (Specification) ····················································································3
6) 시험방법 (Analytical Procedures) ····························································4
7) 시험방법의 밸리데이션 (Validation of Analytical Procedures) ·········4
8) 배치분석 (Batch Analyses) ·······································································4
9) 표준품 또는 표준물질 (Reference Standard or Materials) ··············· 4
10) 용기 및 포장 (Container Closure System) ········································4
11) 안정성 (Stability) ························································································4
나. 임상시험용의약품 (INVESTIGATIONAL MEDICINAL PRODUCTS)
1) 임상시험용의약품의 개요와 조성 (Description and Composition of the
Investigational Medicinal Product) ······························································5
2) 제조원 (Manufacturer(s)) ··········································································5
3) 제조공정 및 공정관리 (Description of Manufacturing Process
and Process Controls) ·····················································································5
4) 불순물 (Impurities) ·····················································································5
5) 규격 (Specification) ······················································································5
6) 시험방법 (Analytical Procedures) ····························································6
7) 시험방법의 밸리데이션 (Validation of Analytical Procedures) ·········6
8) 배치분석 (Batch Analyses) ·······································································6
9) 표준품 또는 표준물질 (Reference Standard or Materials) ··············· 6
10) 용기 및 포장 (Container Closure System) ········································6
11) 안정성 (Stability) ························································································6

2. 치료적 탐색 임상시험 (PHASE II) ··················································7
가. 원료의약품
3.2.S 원료의약품 (DRUG SUBSTANCE)
3.2.S.1 일반정보 (General Information) ······················································7
3.2.S.1.1 명칭 (Nomenclature) ·······································································7
3.2.S.1.2 구조 (Structure) ·············································································8
3.2.S.1.3 일반적 특성 (General Properties) ············································8
3.2.S.2 제조 (Manufacture) ············································································8
3.2.S.2.1 제조원 (Manufacturer(s)) ·································································8
3.2.S.2.2 제조공정 및 공정관리 (Description of Manufacturing Process
and Process Controls) ·····················································································8
3.2.S.3 특성 (Characterization) ·····································································9
3.2.S.3.1 구조 및 기타 특성 (Elucidation of Structure and other
Characteristics) ·······························································································9
3.2.S.3.2 불순물 (Impurities) ········································································9
3.2.S.4 원료의약품의 관리 (Control of Drug Substance) ························9
3.2.S.4.1 규격 (Specification) ···········································································9
3.2.S.4.2 시험방법 (Analytical Procedures) ··············································9
3.2.S.4.3 시험방법의 밸리데이션 (Validation of Analytical Procedures)
······························································································································9
3.2.S.4.4 배치 분석 (Batch Analyses) ························································9
3.2.S.4.5 기준설정근거 (Justification of Specification) ·····························10
3.2.S.5 표준품 또는 표준물질 (Reference Standards or Materials) ····10
3.2.S.6 용기 및 포장 (Container Closure System) ··································10
3.2.S.7 안정성 (Stability) ··············································································10
3.2.S.7.1 안정성 요약 및 결론 (Stability Summary and Conclusions) ······10
3.2.S.7.3 안정성자료 (Stability Data) ·······················································10
나. 임상시험용의약품
3.2.P 임상시험용의약품 (INVESTIGATIONAL MEDICINAL PRODUCTS)
3.2.P.1 임상시험용의약품의 개요와 조성 (Description and Composition
of the Investigational Medicinal Product) ················································11
3.2.P.2 개발경위 (Pharmaceutical Development) ····································11
3.2.P.3 제조 (Manufacture) ········································································11
3.2.P.3.1 제조원 (Manufacturer(s)) ·····························································11
3.2.P.3.2 배치 조성 (Batch Formular) ·························································11

3.2.P.3.3 제조공정 및 공정관리 (Description of Manufacturing Process
and Process Controls) ···················································································11
3.2.P.4 첨가제 관리 (Control of Excipients) ··············································12
3.2.P.5 임상시험용의약품의 관리 (Control of the Investigational
Medicinal Product) ·······················································································12
3.2.P.5.1 규격 (Specifications) ·······································································12
3.2.P.5.2 시험방법 (Analytical Procedures) ··············································12
3.2.P.5.3 시험방법의 밸리데이션 (Validation of Analytical Procedures) ··· 12
3.2..P.5.4 배치 분석 (Batch Analyses) ·························································13
3.2.P.5.5 불순물의 특성 (Characterization of Impurities) ···················13
3.2.P.5.6 기준설정근거 (Justification of Specification) ····························13
3.2.P.6 표준품 또는 표준물질 (Reference Standards or Materials) · 13
3.2.P.7 용기 및 포장 (Container Closure System) ··································13
3.2.P.8 안정성 (Stability) ················································································13
3.2.P.8.1 안정성요약 및 결론 (Stability Summary and Conclusions) ···· 14
3.2.P.8.3 안정성자료 (Stability Data) ···························································14
다. 위약 ·············································································································14
라. 대조약 ··········································································································14
3. 치료적 확증 임상시험 (PHASE Ⅲ) ···············································15
가. 원료의약품
3.2.S 원료의약품 (DRUG SUBSTANCE)
3.2.S.1 일반정보 (General Information) ····················································15
3.2.S.1.1 명칭 (Nomenclature) ·····································································15
3.2.S.1.2 구조 (Structure) ·············································································15
3.2.S.1.3 일반적 특성 (General Properties) ··············································15
3.2.S.2 제조 (Manufacture) ··········································································15
3.2.S.2.1 제조원 (Manufacturer(s)) ·······························································15
3.2.S.2.2 제조공정 및 공정관리 (Description of Manufacturing Process
and Process Controls) ···················································································15
3.2.S.3 특성 (Characterization) ···································································16
3.2.S.3.1 구조 및 기타 특성 (Elucidation of Structure and other
Characteristics) ·····························································································16
3.2.S.3.2 불순물 (Impurities) ··········································································16

3.2.S.4.1 규격 (Specification) ·········································································16
3.2.S.4.2 시험방법 (Analytical Procedures) ············································16
3.2.S.4.3 시험방법의 밸리데이션 (Validation of Analytical Procedures)
····························································································································17
3.2.S.4.4 배치 분석 (Batch Analyses) ··························································17
3.2.S.4.5 기준설정근거 (Justification of Specification) ·····························17
3.2.S.5 표준품 또는 표준물질 (Reference Standards or Materials) ······17
3.2.S.6 용기 및 포장 (Container Closure System) ··································17
3.2.S.7 안정성 (Stability) ··············································································17
3.2.S.7.1 안정성 요약 및 결론 (Stability Summary and Conclusions) ······17
3.2.S.7.3 안정성자료 (Stability Data) ·························································18
나. 임상시험용의약품
3.2.P 임상시험용의약품 (INVESTIGATIONAL MEDICINAL PRODUCTS)
3.2.P.1 임상시험용의약품의 개요와 조성 (Description and Composition
of the Investigational Medicinal Product) ················································18
3.2.P.2 개발경위 (Pharmaceutical Development) ······································18
3.2.P.3 제조 (Manufacture) ············································································18
3.2.P.3.1 제조원 (Manufacturer(s)) ·····························································18
3.2.P.3.2 배치 조성 (Batch Formular) ·························································19
3.2.P.3.3 제조공정 및 공정관리 (Description of Manufacturing Process
and Process Controls) ···················································································19
3.2.P.4 첨가제 관리 (Control of Excipients) ··············································19
3.2.P.5 임상시험용의약품의 관리 (Control of the Investigational
Medicinal Product) ·······················································································19
3.2.P.5.1 규격 (Specifications) ·······································································19
3.2.P.5.2 시험방법 (Analytical Procedures) ··············································19
3.2.P.5.3 시험방법의 밸리데이션 (Validation of Analytical Procedures) ··· 19
3.2..P.5.4 배치 분석 (Batch Analyses) ·························································20
3.2.P.5.5 불순물의 특성 (Characterization of Impurities) ·····················20
3.2.P.5.6 기준설정근거 (Justification of Specification) ····························20
3.2.P.6 표준품 또는 표준물질 (Reference Standards or Materials) · 20
3.2.P.7 용기 및 포장 (Container Closure System) ··································20
3.2.P.8 안정성 (Stability) ················································································20
3.2.P.8.1 안정성요약 및 결론 (Stability Summary and Conclusions) ···· 21

3.2.P.8.3 안정성자료 (Stability Data) ···························································21
다. 위약 ···············································································································21
라. 대조약 ···········································································································21
Ⅲ. 용어 정의 및 약자 (Definitions and Abbreviations) ·········· 22
Ⅳ. 임상 단계별로 요구되는 CMC 정보 요약표(Summaries) ···· 23
Ⅴ.참고자료(References) ··············································································27

 

www.seoho.biz

서호 전북 전주시 덕진구 혁신로 586 (54851)

Tel. 063-214-9325 / Fax. 063-214-9328

seoho@seoho.biz


  1. '21년도 식품안전관리지침(e-book)

    ※ '21년도 식품안전관리지침 e-book으로 보기 2021년도 식품안전관리지침.pdf 미리보기 다운받기 2021년도 식품안전관리지침 서식모음.hwp
    Views11076
    read more
  2. 식품안전관리인증기준(HACCP)평가(심사) 매뉴얼

    식품안전관리인증기준(HACCP)평가(심사) 매뉴얼 Part Ⅰ. 식품안전관리인증기준(HACCP) 심사 개요 / 1 1. 식품안전관리인증기준(HACCP) 심사 개요 ·············&...
    Views3338
    read more
  3. 새로운 식품원료의 안전성 평가 가이드라인

    1. 새로운(한시적) 식품원료 인정제도 ·························&midd...
    Views2666
    read more
  4. [연구결과]미국, 노로바이러스 확산 막는 효과적인 방법은 '손씻기'

    크루즈 여객선에서 올림픽 개최 도시에 이르기까지, 최근 헤드라인을 장식한 주인공인 노로바이러스가 언제 어디서든 발생할 수 있다는 연구결과(*)가 발표됐음. 애리조나 주립대학교 연구진은 노로바이러스 질병 전염을 막는데 가장 좋은 방법을 찾기 위해 실...
    Views83
    Read More
  5. [연구결과]미국, 좋은 식단도 짜면 고혈압 면치 못해

    과일과 채소, 통곡물을 많이 섭취하더라도 식염을 많이 섭취한다면 여전히 고혈압 위험이 높을 수 있다는 연구결과(*)가 고혈압(Hypertension)에 발표됐음. 예전부터 고나트륨식 섭취는 혈압 증가와 관련이 있다고 알려져 왔지만, 일각에서는 체중과 식이에 함...
    Views87
    Read More
  6. Codex에서는식품취급과관련하여,‘필요시안전성보장을위한주변온도관리’를제시

    (Codex) 식품위생의 일반적 원칙의 규범  온도관리:식품의취급방법에있어식품의가열,냉각,조리,냉장과냉동,냉장 또는냉동식품의보관,식품의온도모니터링및필요한장소에식품의안전성과 적절성을 보증하기 위하여 주변온도의 관리하는 설비를 갖추어야 한다. ...
    Views108
    Read More
  7. 2020년 HACCP 지원사업 설명회 자료

    2020년 HACCP 지원사업 설명회 자료
    Views109
    Read More
  8. 유럽식품안전청, 식품 및 사료 중 나노기술에 관한 위해평가 네트워크 연례보고서 발표

    유럽식품안전청(EFSA)은 나노물질에 관한 회원국간 협력 도모를 위해 지난 2010년, 식품 및 사료 중 나노기술에 관한 위해 평가 네트워크를 구축했음. 해당 네트워크는 유럽식품안전청과 회원국간의 정보 교환과 위해평가 활동의 우선순위화를 원활히하자는 취...
    Views121
    Read More
  9. 임상시험용 한약(생약)제제의 품질 가이드라인(민원인 안내서)

    머리말 ·····························&m...
    Views130
    Read More
  10. 「건강기능식품의 기준 및 규격」일부 개정고시 알림

    식품의약품안전처 고시 제2018-12호 「건강기능식품의 기준 및 규격」일부 개정고시 1. 개정 이유 「건강기능식품에 관한 법률」에서 「우수건강기능식품제조기준」 적용을 의무화함에 따라 관련 규정을 삭제하고자 하며, 장용성 캡슐‧과립‧정제의 제피제로 사...
    Views143
    Read More
  11. 2020년 HACCP 인증업소 자체평가

    자체평가 가이드라인[첨부2] 및 자체평가 매뉴얼, 평가표, 고시[첨부3]
    Views195
    Read More
  12. 식품공전 잔류농약 분석법 실무해설서 (제4판)

    「식품공전 잔류농약 분석법 실무 해설서」는 잔류농약 분석과정에 꼭 필요한 분석 화학의 기초지식을 포함하여 분석과정의 상세 원리 및 경험을 바탕으로 한 해설을 포함하고 있어 국내 잔류농약 분석을 수행하는 담당자가 현장에서 사용할 수 있도록 고안된 책...
    Views226
    Read More
  13. 건강기능식품 기능성 평가 가이드(치아건강 개선에 도움편)

    이 평가 가이드[민원인 안내서]는 건강기능식품 기능성원료를 개발하는 연구자 및 영업자에게 기능성(치아건강에 도움)에 대한 바이오마커 등의 정보를 제공함으로써 산업체의 기능성원료 연구개발에 적정을 기하고 효율성을 높이고자 작성되었다. www.seoho.b...
    Views244
    Read More
  14. 식품안전관리인증기준 평가[심사] 매뉴얼

    식품안전관리인증기준 평가[심사] 매뉴얼 1 Ⅰ. 식품안전관리인증기준(HACCP) 심사 개요 1. 식품안전관리인증기준(HACCP) 심사 개요 3 2. 식품안전관리인증기준(HACCP) 심사관 및 지도관 책임과 의무 3 5 Ⅱ. 식품안전관리인증기준(HACCP) 심사 절차 1. HACCP 인...
    Views254
    Read More
  15. 해썹(HACCP) 적용을 추진할 때 절차

    적용절차 식품 제조·가공 업체 및 집단급식소에서 해썹(HACCP) 적용을 추진할 때 절차는 다음과 같다. 해썹(HACCP) 추진팀 구성 및 역할분담 해썹(HACCP)시스템의 확립과 운용을 주도적으로 담당할 해썹(HACCP)팀 구성 품질관리, 생산, 공무, 연구개발 ...
    Views254
    Read More
  16. HACCP 이란?

    추진체계 위해요소 분석이란 “어떤 위해를 미리 예측하여 그 위해요인을 사전에 파악하는 것”을 의미하며, 중요관리점이란 “반드시 필수적으로 관리하여야 할 항목”이란 뜻을 내포하고 있다. 즉 해썹(HACCP)은 위해 방지를 위한 사...
    Views271
    Read More
목록
Board Pagination Prev 1 2 3 Next
/ 3
위로